Bayesian optimal design in population models for haematologic data
✍ Scribed by J. Lynn Palmer; Peter Müller
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 126 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
✦ Synopsis
We introduce a population model to design optimal apheresis schedules to collect blood stem cells from cancer patients. Blood stem cells are collected prior to the patient undergoing high-dose chemoradiotherapy and are returned after this treatment to enable reconstitution of the white blood cell components. Maximizing the number of cells collected in as few aphereses as possible is desirable. We use a longitudinal data model with random effects to describe profiles of individual patients. A hierarchical prior model introduces common mean profiles for patients undergoing different treatments. We find the optimal apheresis schedule for a new patient by minimizing an expected loss over the posterior predictive distribution of the patient's predicted CD34 profile. We implement estimation of the model and solution of the optimal design problem by a simulation approach, which allows us to accommodate arbitrary shapes for the profiles and realistic loss functions that include relative penalties for the number of scheduled stem cell collections and for collecting fewer than a specified target quantity of total collected stem cells. 1998 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract Association analysis of genetic polymorphisms has been mostly performed in a case‐control setting with unrelated affected subjects compared with unrelated unaffected subjects. In this paper, we present a Bayesian method for analyzing such case‐control data when the population is in Hard
## Abstract As the treatments of cancer progress, a certain number of cancers are curable if diagnosed early. In population‐based cancer survival studies, cure is said to occur when mortality rate of the cancer patients returns to the same level as that expected for the general cancer‐free populati
We describe a novel method for assessing the strength of disease association with single nucleotide polymorphisms (SNPs) in a candidate gene or small candidate region, and for estimating the corresponding haplotype relative risks of disease, using unphased genotype data directly. We begin by estimat